Introduction of cyclofem® once-a-month injectable contraceptive in Mexico

Garza-Flores, J.; Olmo, A Morales del; Fuziwara, J.L.; Figueroa, Jacqueline; Alonso, Alina; J, Monroy; Pérez, M; Urbina-Fuentes, Manuel; Guevara, S.J; Cedeno, E; Barrios, Rolando; Ferman, Johanna; Medina, Leopoldo Muñoz; Velázquez, ez Humberto M Uribe; Pérez‐Palacios, Gregorio

doi:10.1016/s0010-7824(98)00062-6

Cited by 11 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 More recently, community-based family planning programmes in Bolivia, Guatemala, Mexico and Peru successfully added injectable contraceptives to the method mix offered to many of their rural clients. [2][3][4][5] Solid evidence exists that community-based health workers can safely screen for medical contraindications to DMPA, 6 and checklists using WHO eligibility criteria have been created to facilitate CBD provision of injectable contraceptives. 7 In spite of this evidence base, paramedical provision of injectable contraception remains rare around the world and is unknown in Africa, where clinic access is often poor and the need is greatest.…”

Section: Introductionmentioning

confidence: 99%

Contraceptive injections by community health workers in Uganda: a nonrandomized community trial

Stanback

Mbonye

Bekiita³

2007

Bull World Health Organ

102

View full text Add to dashboard Cite

Objective To compare the safety and quality of contraceptive injections by community-based health workers with those of clinicbased nurses in a rural African setting.Methods A nonrandomized community trial tested provision of injectable Depo Provera (DMPA) by community reproductive health workers and compared it with routine DPMA provision at health units in Nakasongola District, Uganda. The primary outcome measures were safety, acceptability and continuation rates. Findings A total of 945 new DMPA users were recruited by community workers, clinic-based nurses and midwives. Researchers successfully followed 777 (82% follow-up): 449 community worker clients and 328 clinic-based clients. Ninety-five percent of community-worker clients were "satisfied" or "highly satisfied" with services, and 85% reported receiving information on side-effects. There were no serious injection site problems in either group. Similarly, there was no significant difference between continuation to second injection (88% among clients of community-based workers, 85% among clinic-going clients), nor were there significant differences in other measures of safety, acceptability and quality. Conclusion Community-based distribution (CBD) of injectable contraceptives is now routine in some countries in Asia and Latin America, but is practically unknown in Africa, where arguably the need for this practice is greatest. This research reinforces experience from other regions suggesting that well-trained community health workers can safely provide contraceptive injections.

show abstract

Section: Introductionmentioning

confidence: 99%

Contraceptive injections by community health workers in Uganda: a nonrandomized community trial

Stanback

Mbonye

Bekiita³

2007

Bull World Health Organ

102

View full text Add to dashboard Cite

show abstract

“…[89] As summarized in Table 4, there has been an inconsistent association between oral contraceptive use and yeast vaginitis. Women using COCs have been reported to have an increase in yeast vaginitis,[12, 17] a decrease in yeast colonization[85] or no effect on yeast colonization[16] depending on the study size and design.…”

Section: Is There An Association Between Contraceptive Use and Yeast mentioning

confidence: 99%

The complexity of contraceptives

Achilles

Hillier

2013

Aids

View full text Add to dashboard Cite

“…A range of tools and resources exist for monitoring and evaluation (M&E) of family planning programs ( Adamou et al, 2013 ; Barden O’Fallon & Bisgrove, 2016 ; MEASURE Evaluation, 2018 ). Research studies evaluating pilot introductions of new contraceptive methods—including review of service statistics in some cases—are also well documented in the literature ( Garza-Flores et al, 1998 ; Gribble, Lundgren, Velasquez, & Anastasi, 2008 ; Hubacher, Akora, Masaba, Chen, & Veena, 2014 ; Lundgren et al, 2012 ; Zenger, Shuhua, & Huimin, 1995 ). However, there is a lack of published material to guide the specific process for using monitoring systems to generate data on pilot introductions of new contraceptive technologies in national family planning programs.…”

Section: Introductionmentioning

confidence: 99%

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC)

Stout

Wood

Namagembe³

et al. 2018

Evaluation and Program Planning

View full text Add to dashboard Cite

HighlightsFrom 2014 to 2016, the MOHs of Burkina Faso, Niger, Senegal and Uganda launched pilot introductions of the novel injectable contraceptive DMPA-SC.This manuscript describes a four-phase approach to monitoring DMPA-SC pilot introduction across the four countries.Existing national family planning registers were used to monitor DMPA-SC pilot introductions, with modifications.Comprehensive data from DMPA-SC pilot introduction informed decisions about future investments in the product and scaling product availability nationally.

show abstract

Introduction of cyclofem® once-a-month injectable contraceptive in Mexico

Cited by 11 publications

References 12 publications

Contraceptive injections by community health workers in Uganda: a nonrandomized community trial

Contraceptive injections by community health workers in Uganda: a nonrandomized community trial

The complexity of contraceptives

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC)

Contact Info

Product

Resources

About